Philippines Pharma and Healthcare Sector Report 2024-2025

The Philippines' healthcare system comprises both public and private components. In the Philippines, public healthcare is devolved to local government units, with the central government operating only a few tertiary care and specialist health facilities. In the Philippines, healthcare devolution has contributed to fragmentation, with significant disparities in the quality and availability of care between regions. Because of persistent underfunding, the private healthcare system has been driving growth in healthcare capacity in recent years. The government passed the Universal Health Care Act in 2019 to provide publicly funded health insurance to all Filipinos, which is expected to increase demand for new healthcare facilities and equipment.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Philippines. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Philippines
• Crystallise the forces both driving and restraining this sector in Philippines
• Ascertain Philippines’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Philippines.
• Build a clear picture of trends, output and consumption for specific sub-sectors